Sign In
Buy RVTY
$101.07
+0.680 (+0.677%)
At Close: Jun 03, 2026
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending
07:32am, Friday, 31'st Jan 2025
Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research.
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024
06:00am, Friday, 31'st Jan 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP
Revvity Gears Up for Q4 Earnings: What's in the Offing?
09:40am, Wednesday, 29'th Jan 2025
RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
Revvity (RVTY) Earnings Expected to Grow: Should You Buy?
11:06am, Friday, 24'th Jan 2025
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
01:16pm, Thursday, 23'rd Jan 2025
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity Ignites Scientific Breakthroughs at SLAS2025
08:00am, Thursday, 23'rd Jan 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflow
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test
10:55am, Monday, 13'th Jan 2025
Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance
05:00pm, Sunday, 12'th Jan 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 20
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
09:45am, Tuesday, 31'st Dec 2024
RVTY's strong product portfolio raises optimism about the stock.
Revvity to Present at J.P. Morgan Healthcare Conference
08:00am, Tuesday, 17'th Dec 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. Presiden
Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
12:27am, Monday, 16'th Dec 2024
Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%)
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
12:36pm, Wednesday, 04'th Dec 2024
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
08:00am, Wednesday, 20'th Nov 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critic
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
02:06pm, Tuesday, 05'th Nov 2024
Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
01:40pm, Monday, 04'th Nov 2024
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
